Why Spatial Context Is Redefining TME Biomarker Validity

Non-spatial bulk transcriptomic and immunohistochemistry approaches fail to capture the clinically relevant heterogeneity within tumor tissue — a limitation that spatially resolved transcriptomics technologies are now systematically addressing. Platforms including 10x Genomics Visium and NanoString GeoMx Digital Spatial Profiling (DSP) capture gene expression data while preserving the physical location of cells within tissue sections, enabling researchers to distinguish architecturally distinct zones with very different clinical implications.

The Bristol Myers Squibb spatial transcriptomics assessment profiled 40 tissue sections and 80,024 capture spots, demonstrating that spatial transcriptomics captures hypoxia, necrosis, vasculature, and ECM variation, and can identify anti-correlated tumor versus immune cell distributions in syngeneic cancer models. This level of spatial granularity is inaccessible to conventional profiling methods and is increasingly regarded as a prerequisite for biomarker discovery programs targeting immune checkpoint response.

The University of Calgary spatial transcriptomics study on oral squamous cell carcinoma (OSCC) formalized this architectural distinction by defining tumor core (TC) and leading edge (LE) gene signatures across multiple cancers. The finding that LE signatures correlate with worse clinical outcomes while TC signatures correlate with improved prognosis has direct implications for spatially informed drug targeting. Drug response associations were predicted in silico for each spatial zone, suggesting that whole-tumor approaches may obscure zone-specific therapeutic opportunities.

In non-small-cell lung cancer (NSCLC), spatial trajectory analysis via spatial transcriptomics technology identified EMT gradients in stroma adjacent to tumor regions and detected tumor subclones with differential metastatic potential — findings that could not have been resolved from bulk tissue. Across HNSCC, bladder cancer, OSCC, and NSCLC cohorts, the consistent message is that spatial resolution is no longer optional for TME biomarker programs that aspire to clinical utility.

Immune Checkpoint Blockade: From Bulk Scoring to Spatial Stratification

Spatial and multi-omic profiling now resolves the TME subtypes that correlate with immune checkpoint blockade (ICB) response more accurately than standard PD-L1 scoring — a finding replicated across urothelial cancer, head and neck squamous cell carcinoma, and bladder cancer cohorts. The single largest cluster of evidence in this field addresses anti-PD-1/PD-L1 and anti-CTLA-4 therapies and the challenge of identifying which patient subsets will respond.

In urothelial cancer, LASSO regression-derived TME signatures defined three distinct patterns: stromal-activation, immune-enriched, and immune-suppressive subtypes. The immune-suppressive subtype showed worse prognosis and lower immunotherapy response — a clinically actionable stratification that bulk PD-L1 scoring does not capture. In bladder cancer, integration of spatial PD-L1 scoring with digital immune profiling using hierarchical clustering outperformed standard PD-L1 scoring algorithms in predicting patient survival across a cohort of 193 muscle-invasive bladder cancer patient tumors assayed with four PD-L1 assays.

“Integration of spatial PD-L1 expression with the tumor immune microenvironment outperforms standard PD-L1 scoring in outcome prediction — a finding replicated across urothelial cancer, HNSCC, and bladder cancer cohorts.”

In head and neck squamous cell carcinoma, NanoString GeoMx Digital Spatial Profiling of HNSCC samples revealed that CD4, CD68, CD45, CD44, and CD66b markers — rather than CD8+ T cell density alone — were predictive of ICI therapy outcome. This finding challenges the prevailing assumption that CD8+ TIL density is the dominant spatial biomarker for ICB response and points toward multiplex spatial profiling as the necessary standard.

A South China University of Technology study classified pan-cancer samples into four TIME subtypes based on combined PD-L1 expression and TIL Z-score, demonstrating superior ICB response prediction across multiple datasets compared to PD-L1 alone. BeiGene’s dualmarker framework reinforces this direction, signaling growing recognition that single biomarkers — PD-L1 alone, TMB alone — are insufficient for ICB patient stratification, and that combinatorial biomarker systems integrating spatial TME context will be required for reliable patient selection.

Multi-Omic Integration Outperforms Single-Layer Models for Drug Response

Computational frameworks that integrate transcriptomics, somatic mutations, copy number variation, and DNA methylation consistently outperform single-omic models for drug sensitivity prediction — a finding that has direct implications for how companion diagnostic IP strategies should be structured. The evidence base for this claim spans multiple independent research groups and validation datasets.

The MOLI framework (University of British Columbia) integrates somatic mutation, copy number aberration, and gene expression via type-specific encoding subnetworks, demonstrating improved drug response prediction and clinical relevance. The Max Delbrück Center demonstrated that adding transcriptomic data on top of cancer gene panel features substantially improves drug response prediction in both patient-derived xenografts (PDX) and ex vivo fresh tumor specimens — a finding with immediate translational implications for clinical trial stratification designs.

At Harbin Medical University, 46 subpathway signatures for anticancer drug response were identified using multi-omic integration of gene expression, copy number variation, and DNA methylation across five cancer-drug datasets. Separately, Shenzhen University constructed a tumor mutational burden (TMB) prediction model from 610 differentially expressed genes, 50 miRNAs, and 58 differentially methylated CpG sites in lung adenocarcinoma — demonstrating that TMB itself can be predicted as a multi-omic composite biomarker rather than requiring direct mutational sequencing.

Multi-omic matrix factorization (MOFA) analysis identified 17 damaging mutations, 6 gene expression signatures, 17 DNA methylation features, and 26 transcription-factor activities as candidate biomarkers for olaparib resistance, validated against the Genomics of Drug Sensitivity in Cancer (GDSC) database. This example illustrates how multi-omic integration can generate mechanistically interpretable resistance biomarker sets that single-omic approaches would miss entirely. IP strategies for drug-response companion diagnostics should therefore consider claims encompassing multi-omic input feature architectures, not solely expression-based biomarkers.

AstraZeneca’s spQSP-IO platform signals an additional convergence: spatial transcriptomics data is being incorporated into agent-based quantitative systems pharmacology models to simulate checkpoint inhibitor pharmacodynamics at the whole-patient scale, particularly for NSCLC. This integration of spatial molecular data into pharmacological simulation frameworks represents a frontier where spatial transcriptomics moves from descriptive biomarker discovery into predictive pharmacology, as documented by AstraZeneca‘s Clinical Pharmacology and Quantitative Pharmacology group.

Cell Type Deconvolution and the Tooling Landscape

Cell type deconvolution — the computational resolution of mixed transcriptomic signals into constituent cell type proportions — is a crowded but platform-specific field, with competitive differentiation hinging on performance with FFPE clinical samples, batch effect correction, and integration with specific sequencing platforms. The evidence base documents numerous competing tools, each with distinct methodological approaches and validation datasets.

The SpatialCTD benchmark dataset, developed at Jilin University, encompasses 1.8 million cells from lung, kidney, and liver tumors and was specifically designed to evaluate cell type deconvolution methods for immuno-oncology applications. DeMixT (Harvard University, Department of Statistics) performs tumor-stroma-immune three-component deconvolution. SpatialDDLS (Centro Nacional de Investigaciones Cardiovasculares Carlos III) leverages scRNA-seq to train neural network deconvolution models for spatial transcriptomics spots. SPOTlight (CNAG-CRG) combines scRNA-seq reference data with Visium spatial transcriptomics to enable in situ immune cell mapping for digital pathology.

The pan-cancer single-cell tumor immune atlas (CNAG-CRG / Vall d’Hebron Institute of Oncology) jointly analyzed more than 500,000 cells from 217 patients and 13 cancer types, enabling patient stratification by immune cell composition and applying SPOTlight to spatially map immune populations. scCancer2 (Shanghai Jiao Tong University) developed supervised machine learning classifiers trained on 594 samples from 15 scRNA-seq datasets to annotate TME cells at sub-lineage resolution — a scale of reference data that substantially improves annotation reliability for downstream stratification.

Topological analysis tools are also emerging: STopover (Seoul National University) applies topological methods to compute cell-type colocalization patterns in lung cancer spatial transcriptomics data, while SpaceMarkers (Johns Hopkins University Bloomberg-Kimmel Immunotherapy Institute) infers molecular changes arising from tumor-immune cell-cell interactions in Visium ST data, capturing signals from metastatic, invasive, and immunotherapy-treated lesions. The tooling landscape is actively evolving, with academic groups and commercial entities including NanoString Technologies contributing platform-specific innovations.

Clinical Translation Signals and the Path to IVD-Grade Diagnostics

The most direct clinical translation signal in this dataset comes from Mitra Biotech, which engineered personalized tumor ecosystems from 109 patients, trained a machine learning model on ex vivo tumor microenvironment data, and achieved 100% sensitivity in predicting clinical drug response in a validation cohort of 55 patients. This ex vivo patient tumor explant platform represents the closest current bridge between spatial TME profiling and actionable clinical decision support.

The PERCEPTION framework (National Cancer Institute) was validated against two clinical trial datasets in multiple myeloma and breast cancer, demonstrating that single-cell expression profiles can stratify responders to combination therapy. The ENLIGHT transcriptomics-based computational approach was evaluated on 21 blinded clinical trial datasets, demonstrating prediction capacity in both personalized oncology and clinical trial design settings — a validation scope that signals readiness for prospective clinical integration.

The Memorial Sloan Kettering Cancer Center multimodal study integrated CT imaging, digital PD-L1 IHC, and genomics from 247 advanced NSCLC patients to predict immunotherapy response, reporting AUC performance for the multimodal model. A 17-gene non-immune TME signature — primarily composed of ECM remodeling genes — was identified by an Ajou University study as predictive of brain metastasis after surgical resection of lung adenocarcinoma, with AUC values between 0.845 and 0.858 across multiple classifier algorithms. These AUC values place the signature within the range typically considered clinically informative for prognostic biomarker applications.

Persistent technical barriers to clinical translation include cross-platform normalization and robust computational workflows. NanoString GeoMx DSP studies from Erasmus MC and the University of Queensland highlight technical variability and normalization challenges in spatial transcriptomics data. Regulatory and translational strategies must address data standardization to enable spatial biomarkers to advance from research tools to IVD-grade companion diagnostic applications — a challenge that the FDA and international regulatory bodies are beginning to engage with as spatial profiling platforms enter clinical validation pipelines.

No retrieved results reference regulatory submissions, approved drugs, or prospective randomized controlled trial outcomes directly, underscoring that the field remains predominantly in the translational and retrospective cohort validation phase. The Human Tumor Atlas Network is described as generating genomic and histologic datasets spanning thousands of patients to enable collaborative multi-omic therapeutic discovery — a resource that will accelerate the evidence base for prospective clinical validation.

Emerging Directions: Spatial Proteogenomics and Drug Repurposing Pipelines

Several convergent directions are emerging that combine spatial, multi-omic, and computational modalities in ways that could accelerate TME-stratified drug development beyond the current translational phase. The University of Queensland’s spatial proteogenomic analysis of metastatic recurrent head and neck cancers identified two distinct metabolic states in tumor cells with therapeutic implications, identified alternative treatments via spatial immune profiling, and provided a mechanistic explanation for ICB resistance in metastatic recurrent oropharyngeal squamous cell carcinoma (OPSCC) patients — a population with low ICI response rates below 20%.

The SPiD method (University of Queensland) demonstrates that spatial proteomics-informed deconvolution can identify clinically relevant alternative treatments for patients with low ICI response rates, pointing toward spatially guided treatment selection for refractory populations. This approach — using spatial TME architecture to redirect patients toward non-ICB treatment options — represents a meaningful expansion of the biomarker utility concept beyond response prediction into treatment selection.

Drug repurposing pipelines are also gaining traction. OCTAD (Michigan State University) and scDrug (National Taiwan University) represent emerging pipelines connecting tumor gene expression signatures or scRNA-seq data directly to drug candidate prioritization via perturbagen-induced gene expression matching from large drug libraries. GSK’s PerturbX platform for predicting transcriptional responses to chemical or genetic perturbations across cellular contexts signals that major pharmaceutical organizations are investing in this direction as well.

“Organizations developing ICB companion diagnostics should incorporate spatial profiling platforms into biomarker discovery pipelines — as demonstrated across HNSCC, bladder cancer, OPSCC, and NSCLC cohorts — to improve patient stratification accuracy.”

The deep learning integration layer is also maturing. TESLA integrates gene expression with histological images to annotate immune and tumor cells and detect tertiary lymphoid structures. SPACE-GM applies geometric deep learning to 658 head-and-neck and colorectal cancer samples assayed with 40-plex immunofluorescence to identify spatial motifs predictive of cancer recurrence and immunotherapy survival. ARA-CNN (Medical University of Lublin) was trained on 23,199 H&E image patches from lung cancer sections annotated into 9 tissue classes, predicting tumor mutations and patient survival. In NSCLC, spatial transcriptomic data from 22 samples were used to train a convolutional neural network mapping five cell types from H&E images, validated in independent samples — a workflow that could enable spatial transcriptomics-grade stratification from routine histology slides at scale, as further validated by research published through Nature portfolio journals.